Mobile Health Case Management System for Reducing Pediatric Treatment Abandonment

Learn more about:
Related Clinical Trial
Adjuvant Chemotherapy for High-risk Postenucleation Retinoblastoma A Clinical Study on the Efficacy and Safety of VEC Intravenous Chemotherapy Combined With Conbercept Intravitreal Injection in the Treatment of Retinoblastoma RB Liquid Biopsy Biorepository Topotecan and Melphalan for Retinoblastoma Effect of Anesthetic Drugs on Neurocognitive Function in Children With Retinoblastoma Requiring Multiple Anesthetic Exposure – Preliminary Study Ocular Conservative Treatment for Retinoblastoma : Efficacy of the New Management Strategies and Visual Outcome Nitroglycerin for Intra-arterial Chemotherapy in Pediatric Retinoblastoma. Autonomic Reflexes During Intra-arterial Chemotherapy for Retinoblastoma Therapeutic Recommendations For The Treatment Of Children With A Retinoblastoma Photodynamic Therapy With Visudyne for Human Retinoblastoma: A Preliminary Study Topotecan Episcleral Plaque for Treatment of Retinoblastoma G-CSF Alone or Combination With GM-CSF on Prevention and Treatment of Infection in Children With Malignant Tumor Comprehensive Omics Analysis of Pediatric Solid Tumors and Establishment of a Repository for Related Biological Studies Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Children With Newly Diagnosed Brain Tumor Mobile Health Case Management System for Reducing Pediatric Treatment Abandonment PCI Imaging System in Pediatric Ophthalmology Evaluate Safety and the Oncolitic Adenovirus VCN-01 Activity in Patients With Refractory Retinoblastoma Determining Whether Multiple Anesthesia Exposures Affect Cognitive Function for Retinoblastoma Patients Conservative Treatments of Retinoblastoma Study of Treatment for Patients With Cancer of the Eye -Retinoblastoma Intra-arterial Chemotherapy for Advanced Intraocular Retinoblastoma Photoscreening for Retinoblastoma RCT of Ballon Technique VS Selective Ophthalmic Artery Infusion For the Retinoblastoma Patients Studying Health Outcomes After Treatment in Patients With Retinoblastoma Chemotherapy Treatment for Children With Intraocular Germ-Line Retinoblastoma Genetic Mutations and Environmental Exposure in Young Patients With Retinoblastoma and in Their Parents and Young Healthy Unrelated Volunteers A Study of the Effectiveness of a Local Injection of Chemotherapy for Retinoblastoma Intra-arterial Chemotherapy for Retinoblastoma Intra-arterial Chemotherapy With Melphalan for the Treatment of Retinoblastoma (RTB) in Advanced Intraocular Stage Determination of the Sensitivity and Specificity of a Smartphone Application to Detect Retinoblastoma Phase I Trial of Periocular Topotecan in Retinoblastoma Episcleral Topotecan for Treatment of Group D Retinoblastoma Can Pretreatment MRI be Used to Predict Intra-arterial Chemotherapy Response in Retinoblastoma? CEV With/Without Periocular Carboplatin Chemotherapy for Extraocular Retinoblastoma Chemotherapy With or Without Radiation Therapy or Observation in Treating Young Patients With Advanced Retinoblastoma Who Have Undergone Surgery to Remove the Eye Combination Chemotherapy, Radiation Therapy, and Bone Marrow Transplantation in Treating Patients With Retinoblastoma Intravitreal Carboplatin for the Treatment of Participants With Recurrent or Refractory Intraocular Retinoblastoma Superselective Intra-arterial Chemotherapy Treatment for Retinoblastoma- 5 Year Results From Turkey Intra-arterial Chemotherapy(Chemosurgery) for Retinoblastoma Adjuvant Chemotherapy for High-risk Retinoblastoma After Enucleation Alternating Systemic Chemotherapy and Intra-Arterial Melphalan (IAM) Chemotherapy in Children With Intra-Ocular Retinoblastoma Chemotherapy in Treating Patients With Retinoblastoma New Strategies to Detect Cancers in Carriers of Mutations in RB1 Pilot Study of Topotecan/Vincristine With Subconjunctival Carboplatin for Patients With Bilateral Retinoblastoma Carboplatin Plus Vincristine in Treating Children With Retinoblastoma Combination Chemotherapy and Cyclosporine Followed by Focal Therapy for Bilateral Retinoblastoma Proton Beam Radiation Therapy for Intraocular and Periocular Retinoblastoma Quality of Life in Children Cured of Retinoblastoma Adjuvant Treatment in Extensive Unilateral Retinoblastoma Primary Enucleated (RB SFCE 2009) Cardio-respiratory Events During Ophthalmic Artery Chemotherapy for Retinoblastoma Under a Deep Anesthesia Protocol for the Study and Treatment of Participants With Intraocular Retinoblastoma SPT Screening in Irradiated Hereditary Retinoblastoma Survivors Attention to Retinoblastoma Diagnosed in the Trauma Setting Carboplatin Periocular Injection for Retinoblastoma Morphological Analysis of the Pineal Gland in Pediatric Retinoblastoma Patients Using Magnetic Resonance Imaging Phase II Study Temozolomide for Retinoblastoma Metastatic to the Central Nervous System for Patients From Guatemala Research on the Environment and Children’s Health: Retinoblastoma Intravitreal Injections of Melphalan for Retinoblastoma Efficacy Study of Lucentis in the Treatment of Retinoblastoma Feasibility of Generating Pluripotent Stem Cells From Patients With Familial Retinoblastoma A Study of Intra-Ophthalmic Artery Topotecan Infusion for the Treatment of Retinoblastoma Retinoblastoma Survivor Study: Assessment of General Health and Quality of Life Retinoblastoma Biomarker Study Cancer Biology of Retinoblastoma Intra-arterial Chemotherapy for the Treatment of Intraocular Retinoblastoma Intra-arterial Chemotherapy for Children With Retinoblastoma Molecular Analysis of Retinoblastoma

Brief Title

Mobile Health Case Management System for Reducing Pediatric Treatment Abandonment

Official Title

A Mobile Health (mHealth) Case Management System for Reducing Pediatric Cancer Treatment Abandonment

Brief Summary

      Digital case management systems have the potential to increase compliance with
      protocol-driven treatment, reduce treatment abandonment and ultimately help to close the
      discrepancy in pediatric cancer outcomes between Low and Middle Income Countries (LMICs) and
      high-income countries (HICs). The investigators aim to adapt an open-source digital case
      management platform to incorporate standardized pediatric oncology protocols. Effectiveness
      will be evaluated by provider protocol compliance (primary outcome) and patient treatment
      abandonment rates using the digital case management system as compared to historic controls.
      The study population will include patients diagnosed with Burkitt lymphoma, Diffuse large
      B-cell lymphoma (DLBCL) or retinoblastoma at Bugando Medical Centre in Tanzania.
    

Detailed Description

      Each year, approximately 220,000 children globally are newly diagnosed with cancer. Over 85%
      of these new diagnoses are made in low- and middle-income countries (LMICs). Survival rates
      in LMICs are 5-25% compared to 80% in high-income countries (HICs). One of the primary
      contributors to the discrepancy in survival outcomes between LMICs and HICs is a high rate of
      treatment abandonment, defined as refusal to initiate or failure to complete curative
      treatment. Treatment abandonment rate in Tanzania is higher than in other LMICs (40% compared
      to 10-25%), directly impacting patient survival. In HICs, protocol-driven treatment for
      children with cancer has led to increased treatment compliance and large improvements in
      survival. However, it is often not feasible or appropriate to use protocol-driven treatment
      in LMICs without necessary supportive care, human resources and infrastructure. Not
      surprisingly, protocol-related compliance is lower in LMICs compared to HICs. Digital
      technologies for health (i.e., digital health) can facilitate implementation of and
      compliance with standardized pediatric oncology protocols through step-by-step decision
      support algorithms, reminders and alerts related to patient visits, and timely data for
      health service coordination with allied health providers (e.g., nurses, pharmacists etc.).
      This multidisciplinary team from Duke University and Dimagi Inc. in USA, and Bugando Medical
      Centre (BMC) in Tanzania, proposes to adapt, implement, and evaluate a digital case
      management system, called mNavigator, at BMC to improve health provider compliance with
      standardized pediatric oncology protocols.

      For Aim 1, mNavigator development will initially focus on the two nationally-approved
      protocols for Burkitt lymphoma and retinoblastoma. The treatment for Diffuse large B-cell
      lymphoma (DLBCL) follows the Burkitt lymphoma treatment protocol. Using principles of
      persuasive system design and the Consolidated Framework for Implementation Research (CFIR),
      prompts that guide users through protocol implementation will be used as behavioral triggers
      to assist with perceived ease of use.

      For Aim 2, allied health providers at BMC will receive training on using mNavigator as part
      of an in-country workshop led by the M-PIs. This training will be followed by supported
      implementation. Following this training period, mNavigator will be used to enroll pediatric
      patients at BMC with pre-clinical diagnosis of BL, Diffuse large B-cell lymphoma (DLBCL) or
      Rb, over a period of over one and a half years and manage their care for the duration of
      treatment (up to 3 months for BL and DLBCL, and 4 months for Rb). BMC receives and treats
      approximately 150 patients every year, with an estimated 50 patients annually with Burkitt
      lymphoma (BL), Diffuse large B-cell lymphoma (DLBCL) or Rb. To review historic compliance,
      files of patients diagnosed after 2015 with BL, Diffuse large B-cell lymphoma (DLBCL) and Rb
      (when protocols were introduced) will be abstracted by trained research assistants.
      Compliance with protocol-driven treatment will be monitored using mNavigator. System
      functionality will be assessed. Semi-structured assessments of provider system acceptance and
      usability will be conducted along with elucidating caregiver reported barriers to treatment
      completion.

      Secondary objective is to describe factors that facilitate or inhibit implementation of
      mNavigator.
    


Study Type

Interventional


Primary Outcome

Protocol compliance

Secondary Outcome

 Time to diagnosis (in days)

Condition

Burkitt Lymphoma

Intervention

mNavigator

Study Arms / Comparison Groups

 mNavigator
Description:  Allied health providers will use mNavigator to guide diagnosis and treatment for pediatric cancer patients at Bugando Medical Centre (BMC).

Publications

* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information


Recruitment Status

Other

Estimated Enrollment

95

Start Date

July 23, 2019

Completion Date

February 28, 2022

Primary Completion Date

February 28, 2022

Eligibility Criteria

        There are two categories of participants: Patients with Burkitt Lymphoma, Diffuse large
        B-cell lymphoma or retinoblastoma; and health providers at BMC who participate in testing
        and/or use of mNavigator. Eligibility criteria are as follows:

        A) For patients:

        *All patients will be registered in the pre-diagnosis cohort but, for the purposes of this
        study, primary and secondary outcomes will only be tracked for patients with BL, DLBCL or
        RB once the diagnosis is made.

        Inclusion Criteria:

          -  Inclusion criteria are pediatric oncology patients diagnosed with Burkitt Lymphoma,
             Diffuse large B-cell lymphoma or Retinoblastoma under the age of 18

        Exclusion criteria:

          -  Patients older than 18 years at registration

          -  Patients with diagnoses other than Burkitt lymphoma, Diffuse large B-cell lymphoma or
             retinoblastoma.

        B) For providers:

        Inclusion Criteria:

          -  Must be health provider or staff working at BMC who provides care for cancer patients.

          -  Must be 18 years of age or older.

        Exclusion:

        - Persons younger than 18 years of age.
      

Gender

All

Ages

N/A - N/A

Accepts Healthy Volunteers

No

Contacts

Kristin Schroeder, MD MPH, , 

Location Countries

Tanzania

Location Countries

Tanzania

Administrative Informations


NCT ID

NCT03677128

Organization ID

Pro00094010

Secondary IDs

1R21CA217268-01A1

Responsible Party

Sponsor

Study Sponsor

Duke University

Collaborators

 National Cancer Institute (NCI)

Study Sponsor

Kristin Schroeder, MD MPH, Principal Investigator, Duke University


Verification Date

August 2021